Nexus has been highly acquisitive of late, buying New Zealand private hospital and day surgery owner Evolution Healthcare late last year for between $700m and $800m from Pacific Equity Partners.

Although necessary, the side effects of such high doses of steroids are showing in the bone health of all patients,” Dr Supreet Bajwa, Hip and Knee Replacement specialist from Nexus Day Surgery ...

It was reported during the session that the 30-day results from the TRIOMPHE study are promising for aortic arch treatment in Zone 0 with the NEXUS Aortic Arch Stent-Graft System.

Nexus Day hospitals is on the radar of other buyout firms. ... ENT, orthopaedics, general surgery, dental surgery and other procedures. It was established in September 2013. ...

30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal The data demonstrate statistically ...

Nexus is an aggregation of Australian day hospitals performing ophthalmology, endoscopy, plastic surgery, ENT, orthopaedics, general surgery, dental surgery and other procedures. It was ...

The $2.2bn Australian listed healthcare provider Healius has launched the sale process for its day surgery unit. Read Today's Paper Mind Games. The Australian Plus. ... which owns Nexus Day Hospitals.

As previously stated, the Nexus S costs $199 with a two-year T-Mobile contract, $250 with add-a-line activation and $529 with no contract. Best Buy will limit sales to two Nexus S phones per customer.

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at ...

30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal The data demonstrate statistically ...

30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal Dr. Bradley Leshnower, Professor of ...

--Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105 th ...